GlassScriptPhysician profile
Rajesh Kumar Bagai
NPI 1306866736
$29,843.70
in general payments reported to CMS, 2019-2025
83 companies · $9,331 in 2025
The $9,331 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,447 · 2020: $1,558 · 2021: $2,910 · 2022: $4,445 · 2023: $4,417 · 2024: $4,737 · 2025: $9,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $3,495 · Long Term Medical Supply Or Device Loan: $299 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,409.65 |
| Consulting Fee | $3,495.00 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $281.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,901.49 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $2,465.94 | 2019-2025 | |
| Pfizer INC. | $1,374.42 | 2019-2025 | |
| Janssen Biotech, INC. | $1,287.00 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $1,264.02 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $1,253.81 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $1,212.40 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Abbvie INC. | $1,128.16 | 2019-2025 | Venclexta, Lupron Depot |
| Genentech USA, INC. | $1,122.27 | 2019-2025 | Polivy, Alecensa, Tecentriq |
| Astellas Pharma US INC | $1,094.00 | 2019-2025 | Padcev, Vyloy, Xospata |
| Genzyme Corporation | $1,060.91 | 2019-2025 | |
| Amgen INC. | $1,042.68 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Geron Corporation | $984.56 | 2025 | Rytelo |
| Celgene Corporation | $775.12 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Daiichi Sankyo INC. | $748.82 | 2019-2025 | Enhertu, Injectafer, Datroway |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $547.32 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Seagen INC. | $545.56 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Exelixis INC. | $454.43 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $451.07 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $419.00 | 2020-2025 | |
| Puma Biotechnology, INC. | $416.69 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $415.66 | 2023-2025 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $335.97 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $318.82 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $278.17 | 2019-2023 | Imbruvica, Epkinly |
| Array Biopharma INC | $268.28 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $267.88 | 2022-2025 | |
| Genmab U.S., INC. | $246.27 | 2023-2025 | Tivdak, Epkinly |
| Mirati Therapeutics, INC. | $243.85 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $223.12 | 2019-2025 | Alunbrig, Iclusig, Vpriv |
| Alexion Pharmaceuticals, INC. | $222.92 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $221.24 | 2021-2025 | Bavencio |
| Caris Mpi, INC. | $219.82 | 2025 | Mi Cancer Seek |
| Inari Medical, INC. | $198.79 | 2022 | |
| Gilead Sciences, INC. | $195.43 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $179.63 | 2023-2025 | Zoladex, Quzyttir |
| Jazz Pharmaceuticals INC. | $173.22 | 2021-2025 | |
| Kyowa Kirin, INC. | $172.54 | 2021-2025 | Poteligeo |
| Taiho Oncology, INC. | $168.70 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $160.14 | 2019-2025 | Onivyde |
| Servier Pharmaceuticals LLC | $146.36 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $134.94 | 2023-2025 | Qinlock, Romvimza |
| Karyopharm Therapeutics INC. | $133.24 | 2020-2024 | Xpovio |
| Penumbra, INC. | $131.66 | 2022 | |
| Blueprint Medicines Corporation | $130.89 | 2021-2025 | Ayvakit |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Pharmaessentia USA Corporation | $123.65 | 2023-2025 | Besremi |
| Adc Therapeutics America, INC. | $115.33 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $114.83 | 2020-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $107.06 | 2022-2025 | |
| Beigene USA, INC. | $105.78 | 2023-2024 | Brukinsa |
| Springworks Therapeutics, INC. | $104.64 | 2024-2025 | Ogsiveo |
| Sanofi-Aventis U.S. LLC | $99.00 | 2019 | |
| Beone Medicines USA, INC. | $92.05 | 2025 | Brukinsa, Tevimbra |
| Tempus Ai, INC | $76.50 | 2024 | Xt Cdx |
| Clovis Oncology, INC. | $76.42 | 2021 | |
| Adaptive Biotechnologies Corporation | $73.66 | 2025 | Clonoseq |
| Epizyme, INC. | $70.58 | 2021-2022 | |
| Syndax Pharmaceuticals, INC. | $59.27 | 2025 | |
| Stemline Therapeutics INC. | $51.88 | 2024-2025 | Orserdu |
| Teva Pharmaceuticals USA, INC. | $37.76 | 2019 | |
| Myovant Sciences INC. | $34.75 | 2022 | |
| Eusa Pharma (US) LLC | $32.68 | 2022 | |
| Acrotech Biopharma INC. | $30.87 | 2021 | |
| Progenics Pharmaceuticals, INC. | $28.54 | 2025 | |
| Cti Biopharma Corp. | $28.19 | 2023 | Vonjo |
| Kite Pharma, INC. | $26.95 | 2025 | Yescarta |
| Verastem, INC. | $26.28 | 2019-2020 | |
| Aurobindo Pharma USA, INC. | $25.23 | 2019 | |
| Morphosys, US INC. | $23.10 | 2021 | |
| Boston Scientific Corporation | $21.59 | 2024 | |
| Amneal Pharmaceuticals LLC | $18.95 | 2025 | Alymsys |
| Tesaro, INC. | $18.58 | 2019 | |
| G1 Therapeutics, INC. | $18.35 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.11 | 2019 | |
| Shire North American Group INC | $18.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.07 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $15.97 | 2025 | Danziten |
| Coherus Oncology, INC. | $15.06 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.34 | 2022 | |
| Foundation Medicine, INC. | $11.44 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Bagai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.